# PSMD2

Source: https://onco.cc/targets/psmd2/  
OnCo record `psmd2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.

## Summary

Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.

Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.94, genetic association 0.00, clinical 0.99).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: proteasome 26S subunit ubiquitin receptor, non-ATPase 2; 26S proteasome non-ATPase regulatory subunit 2; S2; P97; TRAP2; MGC14274; Rpn1
- Tags: cancer-genes-wave
- Symbol: PSMD2
- Class: other
- Biology: Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Binds to the intracellular domain of tumour necrosis factor type 1 receptor. The binding domain of TRAP1 and TRAP2 resides outside the death domain of TNFR1. Locus 3q27.1 (HGNC).
- Where found: Multiple myeloma: Open Targets association 0.60 with plasma cell myeloma (MONDO_0009693); Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908); Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9559: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9559
- UniProt Q13200: https://www.uniprot.org/uniprotkb/Q13200/entry
- NCBI Gene 5708: https://www.ncbi.nlm.nih.gov/gene/5708
- Ensembl ENSG00000175166: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175166

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/psmd2.json